Arbutus Biopharma | Investor Presentation Deck | 28 slides

Arbutus Biopharma · 2023-03
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

28
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
present_solution
04
Includes a legend for technical acronyms at the bottom.summarize
05
The chart uses a Gantt-style visualization to represent drug development stages.plan_implementation
06
The slide uses a four-column layout to structure the disease overview.establish_context
Open slide detailBeat · Problem
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
The slide uses a process-oriented diagram to show how three distinct mechanisms of action (MOAs) combine to lead to a clinical outcome.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
Includes a schematic of the GalNAc-linker-RNAi construct and a bar chart illustrating the suppression of various HBV transcripts.present_solution
Open slide detailBeat · Solution
10
The slide outlines the study structure for a clinical trial, categorizing cohorts by dosage and patient status (HBV DNA +/-).present_framework
Open slide detailBeat · Solution
11
Data presented at EASL 2022 and AASLD 2022.analyze_data
Open slide detailBeat · Solution
12
The slide displays longitudinal data for cohorts E, F, I, J, G, and K, highlighting individual patient responses and key clinical outcomes.show_traction
Open slide detailBeat · Solution
13
The slide displays 8 individual patient case studies (Pt 46, 51, 52, 53, 56, 58, 59, 60, 61).show_traction
Open slide detailBeat · Solution
14
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.analyze_data
Open slide detailBeat · Solution
15
The slide uses a bulleted list with custom circular icons to present clinical safety findings.summarize
Open slide detailBeat · Solution
16
Data presented at AASLD 2022.summarize
Open slide detailBeat · Solution
17
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.plan_implementation
Open slide detailBeat · Solution
18
The slide outlines a clinical trial design with two main arms involving AB-729, VTP-300, and optional Nivolumab.plan_implementation
Open slide detailBeat · Solution
19
The slide details a specific licensing deal, including financial terms and partner background.cite_precedent
Open slide detailBeat · Solution
20
The slide uses a three-column layout to explain the scientific basis and benefits of the drug.present_solution
Open slide detailBeat · SolutionLoop · Jobs To Be Done
21
Includes IC50 value and IFN-y fold increase data from patient samples.show_traction
Open slide detailBeat · SolutionLoop · Jobs To Be Done
22
The slide uses a three-column layout to highlight the core benefits of the product.present_solution
Open slide detailBeat · SolutionLoop · Jobs To Be Done
23
Includes both longitudinal efficacy data (line chart) and pharmacokinetic data (bar charts) comparing plasma vs liver concentrations.show_traction
Open slide detailBeat · Solution
24
establish_context
Open slide detailBeat · Solution
25
The slide maps the viral genome to specific drug targets and highlights partnerships with X-Chem and Proteros.present_solution
Open slide detailBeat · Solution
26
The slide highlights key therapeutic advantages of the candidate drug.present_solution
Open slide detailBeat · Solution
27
The slide uses a table to present a timeline of clinical milestones.plan_implementation
Open slide detailBeat · Solution
28
state_next_steps
Open slide detailBeat · Solution